Comparative Pharmacology
Head-to-head clinical analysis: ANHYDRON versus DIURIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANHYDRON versus DIURIL.
ANHYDRON vs DIURIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Inhibits sodium reabsorption in the distal convoluted tubule by blocking the sodium-chloride symporter, leading to increased excretion of sodium, chloride, and water.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
Adults: 500 mg to 1000 mg orally once or twice daily; maximum 2000 mg per day.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Terminal elimination half-life is 6-15 hours (mean 10 hours). In renal impairment, half-life can exceed 24 hours.
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
Primarily renal (90-95% excreted unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic